Harmony Biosciences Holdings, Inc. (HRMY) stock
Close on Nov 13, 2026Market cap $1.97BP/E 11.1Yield –
Harmony Biosciences Holdings, Inc. grew revenue 19.8% to $989.36M over the twelve months to Sep 30, 2026. Operating income fell 2.8% to $219.36M, moving the operating margin from 27.3% to 22.2%. Free cash flow was $347.89M, up 59.1% from a year earlier. At the latest close the market valued the company at $1.97B, 11.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.97B
- P/E ratio
- 11.1
- Price to sales
- 1.99
- Price to book
- 1.83
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $989.36M
- Net income
- $178.60M
- EPS, diluted
- $3.03
- Free cash flow
- $347.89M
- Book value per share
- $17.97
- Diluted shares
- 60M
Trading
- Next earnings
- Feb 23, 2027 (estimated, before the open)
- Previous close
- $33.80
- Open
- $34.49
- Day's range
- $33.01 – $34.49
- Volume
- 844,895
- Average volume (20 days)
- 1,218,843
- Index membership
- S&P SmallCap 600 (since Nov 2021), Russell 2000 (since Dec 2020), Russell 3000 (since Feb 2021)
- Beta (5 years)
- 0.93
- 52-week range
- $25.90 – $43.49
- RSI (14 days)
- 36.4
- Volatility (1 year)
- 40.6%
- Relative volume
- 0.87×
- WACC
- 9.5%
On 2 of our idea lists: Magic Formula, Undervalued and financially sound
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | HRMY | S&P 500 | Difference | HRMY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -8.8% | -3.0% | −5.8 pts | ||
| 3 months | -12.3% | -2.8% | −9.5 pts | ||
| Year to date | -9.8% | +11.5% | −21.3 pts | ||
| 1 year | -1.5% | +13.5% | −15.0 pts | ||
| 3 years | +39.3% | +77.7% | −38.4 pts | +11.7% | +21.1% |
| 5 years | -20.6% | +72.6% | −93.2 pts | -4.5% | +11.5% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Harmony Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Results
About Harmony Biosciences
Pharmaceutical Preparations
Harmony Biosciences is a commercial-stage neuroscience company focused on developing and commercializing therapies for patients living with rare neurological diseases. Its therapeutic portfolio spans sleep and wake disorders, rare epilepsies, and neurobehavioral conditions. The company's lead commercial product is WAKIX, a selective histamine 3 receptor antagonist/inverse agonist administered once daily for the treatment of excessive daytime sleepiness and cataplexy in adult and pediatric narcolepsy patients. Harmony also advances a clinical pipeline of next-generation pitolisant formulations, orexin receptor agonists, and serotonin receptor agonists. The company sells its commercial therapies to specialty pharmacies and distributors, including Caremark, Accredo Health Group, and PANTHERx Specialty Pharmacy, which supply patients.
Company profile, executives and historyHarmony Biosciences stock: common questions
What is Harmony Biosciences's stock price?
HRMY closed at $33.76 on Nov 13, 2026, down 0.12% on the day. Over the past 52 weeks it traded between $25.90 and $43.49.
What is Harmony Biosciences's market cap?
Harmony Biosciences was worth $1.97B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is HRMY's P/E ratio?
HRMY trades at 11.1 times earnings, based on diluted earnings per share of $3.03 over the twelve months to Sep 30, 2026.
How much revenue does Harmony Biosciences make?
Harmony Biosciences reported revenue of $989.36M for the twelve months to Sep 30, 2026, up 19.8% from a year earlier.
Does Harmony Biosciences pay a dividend?
No. Harmony Biosciences has not paid a cash dividend over the last twelve months.
When does Harmony Biosciences report earnings next?
Harmony Biosciences is expected to report Q4 FY2026 results on Feb 23, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has HRMY stock performed over the past year?
Including dividends, HRMY returned -1.5% over the past year, against +13.5% for the S&P 500.
How many HRMY shares are sold short?
7M shares were sold short at the latest FINRA report, 13.01% of the float, or 5.6 days of average trading volume.
Who are Harmony Biosciences's competitors?
Companies most similar to Harmony Biosciences by business, industry and size include AXSM, ACAD, PTCT, IONS, SRPT.
See a number that looks wrong?